Business Context and Reporting Period
Apyx Medical Corp (APYX) is a surgical aesthetics company focused on Helium Plasma Platform Technology products, including Renuvion, J-Plasma, and the AYON Body Contouring System. The company operates two primary segments: Surgical Aesthetics and OEM. This summary covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Net Sales | $13.9 million | $26.4 million |
| Gross Profit | $8.9 million | $16.8 million |
| Gross Margin | 63.9% | 63.7% |
| Net Loss (Attributable to Stockholders) | $(3.2) million | $(5.4) million |
| Loss Per Share (Basic & Diluted) | $(0.07) | $(0.12) |
| Cash and Cash Equivalents | $27.6 million (as of June 30, 2026) | N/A |
| Long-Term Debt (Net) | $35.3 million | N/A |
| Working Capital | $43.8 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22.1% ($2.5 million) for the three months and 26.8% ($5.6 million) for the six months ended June 30, 2026, compared to the prior year periods.
- Segment Performance: The Surgical Aesthetics segment drove growth with a 28.1% increase (three months) and 31.7% increase (six months), attributed to the commercial launch of the AYON system, increased international generator sales, and higher handpiece volume. The OEM segment saw a 12.0% decline in the three-month period but remained flat year-to-date.
- Profitability: Gross margin improved to 63.9% (three months) and 63.7% (six months) from 62.3% and 61.3% in the prior year, respectively, due to favorable product mix. However, the company continues to report net losses, though the loss narrowed compared to the prior year.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 23.9% (three months) primarily due to stock-based compensation for the new Executive Chairman and increased advertising. Professional services decreased 18.2% due to lower consulting fees.
- Cash Flow: Net cash used in operating activities increased to $4.1 million for the six months ended June 30, 2026, from $1.9 million in the prior year, driven by bonus payments and inventory procurement.
Guidance, Outlook, and Risks
- Product Launches: The company received expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction in May 2026 and commenced a limited commercial launch in late June 2026.
- Market Outlook: Management anticipates that the widespread use of GLP-1 receptor agonists (e.g., Wegovy, Mounjaro) will initially impact revenue but ultimately drive demand for body contouring procedures to address loose skin, creating a tailwind for Renuvion sales.
- Liquidity: The company has incurred recurring net losses and anticipates continued losses in the near term. It plans to fund operations through existing cash, product sales, and potential additional equity or debt financing. There is no certainty that additional financing will be available on acceptable terms.
- Debt Covenants: The company is subject to financial covenants under its Perceptive Credit Agreement, including trailing twelve-month revenue targets for the Surgical Aesthetics segment ($52.4 million for 2026) and a maximum operating expense target ($45.0 million for 2026). As of June 30, 2026, the company was in compliance.
- Legal Contingencies: The company faces multiple product liability lawsuits and a new patent infringement suit filed in July 2026. While management believes it has meritorious defenses, potential losses could be material if insurance coverage is insufficient or disclaimed. Estimated probable losses for existing product liability matters range from $1.6 million to $1.8 million.
Investor Verification Checklist
- Debt Covenant Compliance: Verify continued adherence to the $52.4 million revenue target and $45.0 million operating expense cap for 2026 to avoid default on the Perceptive Credit Agreement.
- GLP-1 Market Impact: Monitor the actual correlation between GLP-1 drug adoption and the volume of body contouring procedures to validate management's "tailwind" thesis.
- Legal Exposure: Track the status of the July 2026 patent infringement lawsuit and the resolution of existing product liability claims to assess potential uninsured losses.
- Cash Burn Rate: Review the trajectory of operating cash outflows ($4.1 million in six months) against the $27.6 million cash balance to determine the runway before additional financing is required.
- AYON Adoption: Assess the commercial uptake of the newly launched power liposuction feature for the AYON system as a key growth driver.